Catch up on the top radiology content of the past week.
|Articles|April 14, 1999
Agfa and Mitra form joint venture
PACS developers Agfa of Mortsel, Belgium, and Mitra of Waterloo, Ontario, have formed a joint-venture company called Impax Technology to develop and sell PACS software based on Agfa’s Impax product line. The new company will be headed by Mitra chief
Advertisement
PACS developers Agfa of Mortsel, Belgium, and Mitra of Waterloo, Ontario, have formed a joint-venture company called Impax Technology to develop and sell PACS software based on Agfas Impax product line. The new company will be headed by Mitra chief executive Eric Peterson and will also sell Impax software to other companies.
Agfa has become the industrys leading PACS company thanks largely to the Impax software, which Mitra developed for Agfa. The companies have been in discussions for the last several months about restructuring their eight-year relationship. The joint-venture deal allows Agfa to maintain access to the Impax software while creating a new pool of potential OEM customers for Mitra. Impax Technology will be based in Waterloo.
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging's Weekly Scan: September 27 — October 3
2
The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 1
3
Raising Questions on the Prognostic Value of Fractional Flow Reserve from CCTA
4
FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection
5